Table 1.
Sociodemographic characteristics for placebo and ketamine interventions.
| Placebo | Ketamine | |||
|---|---|---|---|---|
| Clinical outcome 24 h after infusion (n) | Responders (1)a | Non-responders (23) | Responders (12)a | Non-responders (12) |
| Sex (M/F) | 0/1 | 7/16 | 3/9 | 4/8 |
| Age (Mean ± SD) | 56 | 43.1 ± 12.5 | 42.6 ± 14.7 | 44.8 ± 10.3 |
| Pretreatment MADRS | 38 | 26.8 ± 4.2 | 27.6 ± 5.8 | 27.1 ± 3.9 |
| 24 h MADRS | 19 | 27.4 ± 4.9 | 17.4 ± 7.5b | 25.1 ± 4.0 |
| ΔMADRS (% changes from 24 h to pretreatment) | 50% | -2.5% ± 10.0% | 35.1% ± 28%b | 7.2% ± 10.0% |
MADRS Montgomery–Åsberg Depression Rating Scale.
aResponders were defined by at least 30% improvement of depressive symptoms assessed by MADRS score after 24 h after interventions.
bBetween group comparisons only performed for the ketamine intervention. The results showed that responders to ketamine had significant lower MADRS score 24 h after infusion compared to non-responders (F(1,22) = 9.80, p = 0.005); responders to ketamine had significant higher improvement on MADRS score 24 h after infusion compared to non-responders (F(1,22) = 10.63, p = 0.004). No significant was found for other demographic characteristics (p values > 0.65).